| Literature DB >> 16501760 |
Wilson Mayrink1, Ana Cristina de Carvalho Botelho, Paulo Araújo Magalhães, Sebastião Mariano Batista, Antonio de Oliveira Lima, Odair Genaro, Carlos Alberto da Costa, Maria Norma de Melo, Marilene Susan Marques Michalick, Paul Williams, Magno Dias, Waleska Teixeira Caiaffa, Evaldo do Nascimento, George Luiz Lins Machado-Coelho.
Abstract
The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16501760 DOI： 10.1590/s0037-86822006000100003
Source DB: PubMed Journal: Rev Soc Bras Med Trop ISSN： 0037-8682 Impact factor: 1.581